New data reinforce the benefit of early preventative treatment with Roche ’s Hemlibra for babies with severe haemophilia A
Phase III HAVEN 7 primary data presented at ASH 2023 provide additional confidence in the favourable efficacy and safety profile of subcutaneous Hemlibra given soon after birth1At nearly two years median follow-up in the descriptive, single-arm study, no babies experienced spontaneous bleeds requiring treatment, and all treated bleeds were as a result of trauma1Safety results were consistent with previous studies of Hemlibra, with no new safety signals observed1The HAVEN 7 study was developed in collaboration with the haemophilia A community, to generate additional evidence for the prophylactic treatment of infants with ha...
Source: Roche Investor Update - December 9, 2023 Category: Pharmaceuticals Source Type: news
Palestinian Families Seek Medical Care Outside Besieged Gaza
ARISH, Egypt—Nazha Abu Dhaahir was relieved when her 7-year-old son Yousef was chosen to leave the Gaza Strip for Abu Dhabi for treatment of his hemophilia, which can render any injury fatal. But that meant leaving two sons who have the same blood disorder in a war zone. She and Yousef rushed to…#arish #egypt #nazhaabudhaahir #gazastrip #abudhabi #hemophilia #yousef #gaza #emirati #sinaipeninsula (Source: Reuters: Health)
Source: Reuters: Health - December 8, 2023 Category: Consumer Health News Source Type: news
Contaminated blood scandal victims say Rishi Sunak 'should be ashamed' after PM was 'forced to do right thing' and compensate families quickly following humiliating Tory revolt
The Haemophilia Society said Rishi Sunak 'should be ashamed' that it took political pressure and public opinion to force the UK Government 'to do the right thing'. (Source: the Mail online | Health)
Source: the Mail online | Health - December 5, 2023 Category: Consumer Health News Source Type: news
Sanofi CEO under pressure to woo investors after spending shock
[1/2] Paul Hudson, chief executive officer of Sanofi, speaks during the annual results news conference at the company's headquarters in Paris, France, February 4, 2022. REUTERS/Benoit Tessier/File Photo Acquire Licensing Rights Dec 5 (Reuters) - Sanofi's (SASY.PA) CEO is under pressure to tell…#paulhudson #sanofi #hudson #danlyons #denver #dupixent #haemophilia #altuviiio #beyfortus #tzield (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2023 Category: Consumer Health News Source Type: news
Sernova Receives Orphan Drug and Rare Pediatric Disease Designations for its Hemophilia A Program from FDA
LONDON, Ontario and WINDHAM COUNTY, Conn., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Sernova Corp. SVA SEOVF (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, today announced the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare…#ontario #windhamcounty #conn #sernovacorp #psh #fda #hemophilia #hemophiliaa #cellpouch #factorviii (Source: Reuters: Health)
Source: Reuters: Health - November 27, 2023 Category: Consumer Health News Source Type: news
EU Approval of AAV5 DetectCDx(TM) Provides Access to Companion Diagnostic for Hemophilia A Gene Therapy
SALT LAKE CITY, Nov. 10, 2023 -- (Healthcare Sales & Marketing Network) -- ARUP Laboratories today announced that it has gained the Conformité Européenne (CE) mark for AAV5 DetectCDx single-site use under the European Union's In Vitro Diagn... Diagnostics, Regulatory ARUP Laboratories, BioMarin Pharmaceutical, AAV5 DetectCDx, hemophilia A (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 10, 2023 Category: Pharmaceuticals Source Type: news
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Higher Today
Activist investor Elliott Investment Management has taken a significant position in BioMarin Pharmaceutical Inc BMRN, engaging with the company on its strategic direction amid leadership changes and the evolving status of its hemophilia treatment, Roctavian. The hedge fund has invested over $1…#activist #bmrn #hemophilia #biomarin #roctavian #isharesbiotechnology #ibb #medicare #jeanjacquesbienaime #alexanderhardy (Source: Reuters: Health)
Source: Reuters: Health - November 7, 2023 Category: Consumer Health News Source Type: news
Roche to present new data at ASH 2023 showcasing breadth of haematology portfolio spanning 10 different types of blood disorders
Basel, 2 November 2023 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it will be presenting more than 45 abstracts at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, spanning 10 haematology indications.New data reflect Roche ’s commitment to advancing treatment standards even further to help improve the lives of people with blood disorders. This includes new areas, as well as diseases where its medicines have already changed the standard of care, such as haemophilia A, diffuse large B-cell lymphoma (DLBCL) and follicu lar lymphoma (FL). These data also support Roche’s mission to dev...
Source: Roche Investor Update - November 2, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecen...
Source: Roche Media News - October 19, 2023 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news
Emicizumab Can Delay Immunosuppressive Tx in Acquired Hemophilia A
(MedPage Today) -- Early emicizumab (Hemlibra) prophylaxis alone prevented clinically relevant bleeds in patients with newly diagnosed acquired hemophilia A, while avoiding the infectious complications of immunosuppressive therapy in this vulnerable... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - October 19, 2023 Category: Hematology Source Type: news
Kerala Proved Good Governance Vital in a Pandemic
This article was supported by the Sabin Vaccine Institute and Internews.
IPS UN Bureau Report
Follow @IPSNewsUNBureau
!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?'http':'https';if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+'://platform.twitter.com/widgets.js';fjs.parentNode.insertBefore(js,fjs);}}(document, 'script', 'twitter-wjs');
Lawmakers Call on G20 to Prioritise Spending on Youth, Gender, and Human Security
Politics Behind the Removal of Mughal History From Textbooks Say Academics (Source: IPS Inter Press Service - Health)
Source: IPS Inter Press Service - Health - October 6, 2023 Category: International Medicine & Public Health Authors: Ranjit Devraj Tags: Asia-Pacific COVID-19 Featured Headlines Health Humanitarian Emergencies TerraViva United Nations India IPS UN Bureau IPS UN Bureau Report Source Type: news
Concizumab May Be Effective Prophylaxis for Hemophilia A or B With Inhibitors
FRIDAY, Sept. 1, 2023 -- Patients with hemophilia A or B with inhibitors have a lower annualized bleeding rate with concizumab than with no prophylaxis, according to a phase 3 study published online Aug. 31 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 1, 2023 Category: Pharmaceuticals Source Type: news
Hemophilia: Concizumab, a New Treatment Option? Hemophilia: Concizumab, a New Treatment Option?
The results are from the prospective, multicenter, phase 3 explorer7 trial, involving 133 patients, including 80 with hemophilia A and 53 had hemophilia B.MDedge News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 31, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Concizumab Prophylaxis Reduced Bleeding Rates in Hemophilia
(MedPage Today) -- Compared with on-demand treatment, prophylaxis with concizumab -- designed to achieve hemostasis in all hemophilia types -- reduced annualized bleeding rates among patients who have hemophilia A or B with inhibitors, the... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 30, 2023 Category: Hematology Source Type: news
